Browse studies

Find your next paid study

13 recruiting studies matching your filters

A Phase 1a/1b Study of the Selective Tyrosine Kinase Inhibitor NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)

Phase 1a/1b dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-330, determine the recommended Phase 2 dose (RP2D), and…

Locally Advanced Solid TumorMetastatic Solid Tumor

Estimated

~$10 – $8,750

Nuvalent Inc.NCT06521554